Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Immunic's Conference Participation: Immunic, Inc. will have its CEO, Daniel Vitt, participate in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference on December 4, 2025, and will also hold one-on-one investor meetings during the event.
Lead Development Program: The company's lead program, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, following promising phase 2 results.
Additional Drug Development: Immunic is also developing IMU-856, aimed at gastrointestinal diseases, and IMU-381, a next-generation molecule currently in preclinical testing, targeting specific gastrointestinal needs.
Forward-Looking Statements Caution: The press release includes cautionary statements regarding forward-looking statements, highlighting risks and uncertainties that could affect the company's future operations and clinical trial outcomes.
Trade with 70% Backtested Accuracy
Analyst Views on IMUX
About IMUX
About the author

Immunic Completes Enrollment for Phase 3 Trials of Vidofludimus Calcium in MS, Top-Line Data Expected by End of 2026
- Trial Enrollment Completion: Immunic has completed enrollment of 2,221 patients across over 100 sites in 15 countries for its Phase 3 ENSURE-1 and ENSURE-2 trials, with top-line data expected by the end of 2026, which will provide critical clinical evidence for multiple sclerosis treatment.
- Positive Clinical Data: The Phase 2 CALLIPER trial demonstrated that Vidofludimus Calcium significantly reduced the 24-week confirmed disability worsening rate in progressive multiple sclerosis patients, achieving positive effects even in those without baseline inflammatory markers, reinforcing its neuroprotective mechanism potential.
- Long-Term Safety Data: In the Phase 2 EMPhASIS trial, 92.3% of patients remained free of confirmed disability worsening events at week 144, indicating good long-term safety and tolerability of Vidofludimus Calcium, potentially offering patients greater independence.
- Intellectual Property Protection: Immunic received a Notice of Allowance from the USPTO for dose strengths of Vidofludimus Calcium in progressive multiple sclerosis, with intellectual property protection extending to 2041, enhancing the company's competitive position in the market.

Immunic Completes Enrollment for Phase 3 Trials of Vidofludimus Calcium, Top-Line Data Expected by End of 2026
- Trial Enrollment Completed: Immunic has completed enrollment for its twin Phase 3 ENSURE trials of Vidofludimus Calcium in relapsing multiple sclerosis, with top-line data expected by the end of 2026, which will significantly bolster the company's leadership position in the neurology sector.
- Efficacy Data Significant: Phase 2 CALLIPER trial results demonstrated that Vidofludimus Calcium significantly reduced confirmed disability worsening events over 24 weeks and increased disability improvement rates, indicating the drug's potential to reshape treatment paradigms in multiple sclerosis.
- Long-Term Safety Profile: Long-term open-label data from the Phase 2 EMPhASIS trial showed that a substantial majority of patients remained free from confirmed disability worsening events during follow-up, highlighting Vidofludimus Calcium's safety and tolerability in long-term management, thereby enhancing patient quality of life.
- Strengthened Intellectual Property: The U.S. has granted a patent for dose strengths of Vidofludimus Calcium in progressive multiple sclerosis, extending intellectual property protection until 2041, which will provide Immunic with a stronger competitive edge and commercialization potential.






